JPML Eyes Gadolinium Contrast Agent Cases

Law360, New York (October 25, 2007, 12:00 AM EDT) -- As product liability suits against makers of injectable contrast agents that allegedly cause serious health problems in patients with kidney problems continue to pile up, the U.S. Judicial Panel on Multidistrict Litigation is considering consolidation.

A representative for the MDL panel confirmed Thursday that it had received a motion to transfer cases involving product liability claims against the makers of gadolinium-based contrast agents used in MRI testing. The panel has started the process that may lead to the docketing of the MDL case.

Suits against contrast...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.